Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
Small Gtpases|July 9, 2016
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancerHidenori Kitai, Hiromichi EbiCancer Science|December 27, 2024
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to AdaptNoritaka Tanaka, Hiromichi EbiNihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2002
[Rationale for Herceptin in the clinical use]Hiromichi Ebi, Yasutsuna SasakiJCO Precision Oncology|September 14, 2020
Precision Oncology and the Universal Health Coverage System in JapanHiromichi Ebi, Hideaki BandoGan to Kagaku Ryoho. Cancer & Chemotherapy|December 15, 2005
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)]Hironobu Minami, Hiromichi EbiGan to Kagaku Ryoho. Cancer & Chemotherapy|December 24, 2025
[Recent Therapeutic Development Targeting KRAS Mutations in Colorectal Cancer]Hiromichi Ebi, Sachiyo ShirakawaCancers|October 23, 2021
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant CancersYuta Adachi, Ryo Kimura, Kentaro Hirade, et al.Cancer Science|March 12, 2014
Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancersHiromichi Ebi, Anthony C Faber, Jeffrey A Engelman, et al.Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Apoptosis in targeted therapy responses: the role of BIMAnthony C Faber, Hiromichi Ebi, Carlotta Costa, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 26, 2018
[Successful Long-Term Treatment with Intermittent Oxaliplatin Administration for Recurrent Sigmoid Colon Cancer without Developing Neuropathy]Hironori Kitade, Hiromichi Ebi, Kengo Hokkoku, et al.Pageof 8